Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Plans PR “Offense” In 2003 To Support Effort To Remove Access Issue

Executive Summary

PhRMA's reconstituted public affairs program will devote half of its time and staff in 2003 to telling positive stories about the industry

You may also be interested in...



PhRMA Plans DTC Offensive; Patients And Patience Are Keys To PR Strategy

PhRMA's efforts to protect direct-to-consumer advertising in 2003 will follow the philosophy that the best defense is a good offense

PhRMA Plans DTC Offensive; Patients And Patience Are Keys To PR Strategy

PhRMA's efforts to protect direct-to-consumer advertising in 2003 will follow the philosophy that the best defense is a good offense

PhRMA Vows To “Re-Shape” Policy Debate; Will Reach Out To Critics

The Pharmaceutical Research & Manufacturers of America plans to make peace overtures to some of its critics within the healthcare sector as part of a new image strategy heading into 2003

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel